Company / Return on Equity (ROE)
ALNYLAM PHARMACEUTICALS, INC. Return on Equity (ROE) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-2.3%
FY2025
5-year range
-414.6% / -2.3%
FY2021-FY2025
Trend
+99.4%
vs FY2024
Sector context
#53 of 190
Health Care
What the data says
ALNYLAM PHARMACEUTICALS, INC. reports negative total equity of -2.3% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-2.3% in FY2025 with a 5-year CAGR of +56.2%.
Improved from -84.5% to -2.3% over the past 3 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +82.2pp
- 5-Year Change
- +56.2pp
- 10-Year Change
- -
Sector benchmark
#53 of 190 in Health CareTop 28% of 190This company -2.3% Sector average -50.4%
▼
+95.4% above sector average
Key checks
Key Insights
- In FY2025, return on equity (roe) increased 99.4% year-over-year.
- Currently 48.1pp above the Health Care sector average.
- Lowest return on equity (roe) in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.37 (distress zone, below 1.8 threshold)
- Negative profit margin: -12.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -2.3% | +99.4% |
| FY2024 | -414.6% | - |
| FY2023 | - | - |
| FY2022 | -84.5% | -37.1% |
| FY2021 | -61.6% | -5.3% |
| FY2020 | -58.5% | -110.5% |
| FY2019 | -27.8% | +37.6% |
| FY2018 | -44.6% | -60.4% |
| FY2017 | -27.8% | +37.6% |
| FY2016 | -44.6% | -94.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026